西米普利單抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目標 | PD-1 |
| 臨床資料 | |
| 读音 | sem' ip li" mab |
| 商品名 | Libtayo |
| 其他名稱 | REGN-2810, REGN2810, cemiplimab-rwlc |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618054 |
| 核准狀況 | |
| 懷孕分級 | |
| 给药途径 | 靜脈注射 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 藥物動力學數據 | |
| 生物半衰期 | 19 天 |
| 识别信息 | |
| CAS号 | 1801342-60-8 |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6380H9808N1688O2000S44 |
| 摩尔质量 | 143,569.10 g·mol−1 |
西米普利單抗（INN：Cemiplimab）用于治疗皮膚鱗狀細胞癌、基底細胞癌和某些非小細胞肺癌的药物[9] [10]。用于无法以手术治癒的晚期病症[9]。由静脉注射给药[9]。
常见副作用包括甲状腺功能低下造成疲劳和体重增加；肺炎，导致呼吸短促和咳嗽；皮肤反应；甲状腺功能亢进造成出汗和体重增加；及肝脏炎症[9]。其他副作用包括可能有输液反应和肌肉疼痛[10]。孕期使用可能對婴儿有害[10]。它是一种单克隆抗体，可与细胞程式死亡蛋白1（PD-1）结合，使T细胞能够杀死癌细胞[9]。
西米普利單抗于 2018 年及2019 年在美国及欧洲取得医疗使用許可[7] [9]。该药物于 2020 年 7 月在澳大利亚取得医疗使用許可[11]。
参考文獻
[编辑]- ^ Libtayo Australian Prescription Medicine Decision Summary. Therapeutic Goods Administration (TGA). 29 July 2020 [16 August 2020]. （原始内容存档于13 August 2020）.
- ^ AusPAR: Cemiplimab (PDF). Therapeutic Goods Administration (TGA). 9 November 2020 [6 June 2021]. （原始内容 (PDF)存档于7 June 2021）.
- ^ TGA eBS - Product and Consumer Medicine Information Licence.
- ^ Cemiplimab Product information. Health Canada. 25 April 2012 [29 May 2022].
- ^ Summary Basis of Decision (SBD) for Libtayo. Health Canada. 23 October 2014 [29 May 2022].
- ^ Libtayo- cemiplimab-rwlc injection. DailyMed. 25 June 2020 [16 August 2020].
- ^ 7.0 7.1 FDA approves first treatment for advanced form of the second most common skin cancer. U.S. Food and Drug Administration. 28 September 2018 [7 August 2020]. （原始内容存档于8 August 2020）.
本文含有此來源中屬於公有领域的内容。
- ^ Libtayo EPAR. European Medicines Agency (EMA). 24 April 2019 [7 August 2020]. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ 9.0 9.1 9.2 9.3 9.4 9.5 Libtayo EPAR. European Medicines Agency (EMA). 24 April 2019 [7 August 2020]. （原始内容存档于23 June 2020）. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ 10.0 10.1 10.2 Libtayo- cemiplimab-rwlc injection. DailyMed. 25 June 2020 [16 August 2020]. （原始内容存档于17 October 2020）.
- ^ Libtayo Australian Prescription Medicine Decision Summary. Therapeutic Goods Administration (TGA). 29 July 2020 [16 August 2020]. （原始内容存档于13 August 2020）.
